OCULAR MOTOR AND NEUROANATOMIC STUDIES OF SCHIZOPHRENIA
精神分裂症的眼运动和神经解剖学研究
基本信息
- 批准号:6126167
- 负责人:
- 金额:$ 11.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-09-01 至 2003-11-30
- 项目状态:已结题
- 来源:
- 关键词:behavioral genetics bipolar depression clinical research eye movement disorders family genetics human middle age (35-64) human subject mental disorder diagnosis motion perception neuroanatomy neuropathology parietal lobe /cortex prefrontal lobe /cortex saccades schizophrenia smooth pursuit eye movement vision tests visual fields visual fixation visual stimulus young adult human (21-34)
项目摘要
Ocular motor performance provides a powerful behavioral means for
studying what is specifically different about the functioning of
schizophrenia subjects' brains, and for evaluating functional deviations
that are correlated with predisposition for developing this illness.
Identifying and refining schizophrenia-specific ocular motor
abnormalities will serve at least two important functions. First, the
ocular motor system is well understood both functionally and
neuroanatomically. Dysfunction in particular parts of its neural
control system result in characteristic patterns of ocular motor
response. By presenting subjects with the appropriate set of tasks and
monitoring their performance, hypotheses about the location of
neuropathology can be tested. Ocular motor measurement, therefore, can
aid the investigation of schizophrenia's neuropathology. Second,
schizophrenia patients' clinically normal biological relatives seem to
have the same pattern of ocular motor abnormalities as the patients
themselves. These findings suggest that some aspect of ocular motor
system dysfunction is assessing a component of brain functioning closely
associated with a neurobiological predisposition for this illness.
Further research on this phenomenon, therefore, could lead to the
development of highly sensitive indicators of clinically unaffected gene
carriers. A research programme appropriate for these undertakings
requires collecting data on ocular motor performance across a range of
tasks, a strategy we have used with considerable success. It is
remarkable to think that studies of schizophrenia subjects' behavioral
performance can provide consistent and theoretically meaningful
neurologically localizing information. This is exactly the conclusion
that could be drawn with data from some additional clarifying studies.
Research conducted with this grant will allow us to (1) rule out the
possibility that schizophrenia subjects have a primary dysfunction of
their smooth pursuit systems, (2) provide data inconsistent with the
thesis that schizophrenia subjects have dysfunction of either posterior
parietal cortex ocular motor-related regions or frontal eye fields, and
(3) corroborate the hypothesis that the ocular motor abnormalities
observed among schizophrenia subjects are a consequence of dysfunction
in dorsolateral prefrontal cortex and/or its related subcortical
circuitry. These data will be critically important for the success and
efficiency of future functional neuroimaging and genetic linkage
studies, because research with these important, but expensive,
technologies will be suboptimal if they are based on the wrong
behavioral measures. In this regard, it will be especially important to
refine stimulus conditions to the point where measurement error is
reduced as much as is practically feasible, a goal toward which we will
aspire with our proposed research.
Ocular motor performance provides a powerful behavioral means for
studying what is specifically different about the functioning of
schizophrenia subjects' brains, and for evaluating functional deviations
that are correlated with predisposition for developing this illness.
Identifying and refining schizophrenia-specific ocular motor
abnormalities will serve at least two important functions. First, the
ocular motor system is well understood both functionally and
neuroanatomically. Dysfunction in particular parts of its neural
control system result in characteristic patterns of ocular motor
response. By presenting subjects with the appropriate set of tasks and
monitoring their performance, hypotheses about the location of
neuropathology can be tested. Ocular motor measurement, therefore, can
aid the investigation of schizophrenia's neuropathology. Second,
schizophrenia patients' clinically normal biological relatives seem to
have the same pattern of ocular motor abnormalities as the patients
themselves. These findings suggest that some aspect of ocular motor
system dysfunction is assessing a component of brain functioning closely
associated with a neurobiological predisposition for this illness.
Further research on this phenomenon, therefore, could lead to the
development of highly sensitive indicators of clinically unaffected gene
carriers. A research programme appropriate for these undertakings
requires collecting data on ocular motor performance across a range of
tasks, a strategy we have used with considerable success. It is
remarkable to think that studies of schizophrenia subjects' behavioral
performance can provide consistent and theoretically meaningful
neurologically localizing information. This is exactly the conclusion
that could be drawn with data from some additional clarifying studies.
Research conducted with this grant will allow us to (1) rule out the
possibility that schizophrenia subjects have a primary dysfunction of
their smooth pursuit systems, (2) provide data inconsistent with the
thesis that schizophrenia subjects have dysfunction of either posterior
parietal cortex ocular motor-related regions or frontal eye fields, and
(3) corroborate the hypothesis that the ocular motor abnormalities
observed among schizophrenia subjects are a consequence of dysfunction
in dorsolateral prefrontal cortex and/or its related subcortical
circuitry. These data will be critically important for the success and
efficiency of future functional neuroimaging and genetic linkage
studies, because research with these important, but expensive,
technologies will be suboptimal if they are based on the wrong
behavioral measures. In this regard, it will be especially important to
refine stimulus conditions to the point where measurement error is
reduced as much as is practically feasible, a goal toward which we will
aspire with our proposed research.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRETT A CLEMENTZ其他文献
BRETT A CLEMENTZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRETT A CLEMENTZ', 18)}}的其他基金
Identification of distributed neural sources of the auditory steady-state response in psychosis Biotypes
精神病生物型中听觉稳态反应的分布式神经源的识别
- 批准号:
10543156 - 财政年份:2022
- 资助金额:
$ 11.92万 - 项目类别:
5/5 - Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
5/5 - 生物标志物/生物型、早期精神病课程和专业服务 (BICEPS)
- 批准号:
10683289 - 财政年份:2022
- 资助金额:
$ 11.92万 - 项目类别:
Identification of distributed neural sources of the auditory steady-state response in psychosis Biotypes
精神病生物型中听觉稳态反应的分布式神经源的识别
- 批准号:
10373165 - 财政年份:2022
- 资助金额:
$ 11.92万 - 项目类别:
1/2: B-SNIP: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT)
1/2:B-SNIP:高效治疗处方的算法诊断 (ADEPT)
- 批准号:
10298707 - 财政年份:2021
- 资助金额:
$ 11.92万 - 项目类别:
5/5: Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
5/5:B-SNIP Biotype-1 (CLOZAPINE) 中氯氮平的选择性抗精神病反应
- 批准号:
10613498 - 财政年份:2021
- 资助金额:
$ 11.92万 - 项目类别:
5/5: Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
5/5:B-SNIP Biotype-1 (CLOZAPINE) 中氯氮平的选择性抗精神病反应
- 批准号:
10397394 - 财政年份:2021
- 资助金额:
$ 11.92万 - 项目类别:
5/5 BIPOLAR-SCHIZOPHRENIA NETWORK FOR INTERMEDIATE PHENOTYPES (B-SNIP) - Resubmission - 1
5/5 中间表型的双极精神分裂症网络 (B-SNIP) - 重新提交 - 1
- 批准号:
9338010 - 财政年份:2015
- 资助金额:
$ 11.92万 - 项目类别:
4/4-Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP)
4/4-精神病和情感研究领域和中间表型(PARDIP)
- 批准号:
8902951 - 财政年份:2013
- 资助金额:
$ 11.92万 - 项目类别:
4/4-Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP)
4/4-精神病和情感研究领域和中间表型(PARDIP)
- 批准号:
8706963 - 财政年份:2013
- 资助金额:
$ 11.92万 - 项目类别:
4/4-Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP)
4/4-精神病和情感研究领域和中间表型(PARDIP)
- 批准号:
8504490 - 财政年份:2013
- 资助金额:
$ 11.92万 - 项目类别:
相似海外基金
Psilocybin Assisted Psychotherapy for Bipolar Depression: An fMRI Emotional-Processing Pilot Study
裸盖菇素辅助双相抑郁心理治疗:功能磁共振成像情绪处理试点研究
- 批准号:
486939 - 财政年份:2023
- 资助金额:
$ 11.92万 - 项目类别:
Miscellaneous Programs
Repeated Ketamine Infusions for Cognitive Impairment in Treatment-Resistant Bipolar Depression
反复输注氯胺酮治疗难治性双相抑郁症的认知障碍
- 批准号:
486443 - 财政年份:2022
- 资助金额:
$ 11.92万 - 项目类别:
Studentship Programs
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study
裸盖菇素对治疗难治性双相抑郁症的神经生物学作用:情绪处理功能磁共振成像初步研究
- 批准号:
486577 - 财政年份:2022
- 资助金额:
$ 11.92万 - 项目类别:
Studentship Programs
Reward and stress: Developing neuroimaging biomarkers for bipolar depression
奖励和压力:开发双相抑郁症的神经影像生物标志物
- 批准号:
2748645 - 财政年份:2022
- 资助金额:
$ 11.92万 - 项目类别:
Studentship
Theta-burst stimulation for bipolar depression: A randomized controlled trial
θ 爆发刺激治疗双相抑郁症:一项随机对照试验
- 批准号:
469571 - 财政年份:2022
- 资助金额:
$ 11.92万 - 项目类别:
Operating Grants
Cannabidiol Adjunctive Therapy for Acute Bipolar Depression: A Randomized Double-Blind Placebo Controlled Trial
大麻二酚辅助治疗急性双相抑郁症:随机双盲安慰剂对照试验
- 批准号:
444068 - 财政年份:2021
- 资助金额:
$ 11.92万 - 项目类别:
Operating Grants
Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized, Midazolam-Controlled Phase II Clinical Trial
重复氯胺酮输注治疗难治性双相抑郁症:一项随机、咪达唑仑对照的 II 期临床试验
- 批准号:
434675 - 财政年份:2020
- 资助金额:
$ 11.92万 - 项目类别:
Operating Grants
Next Generation Drugs for Bipolar Depression and Maintenance
治疗双相抑郁症和维持治疗的下一代药物
- 批准号:
9555300 - 财政年份:2018
- 资助金额:
$ 11.92万 - 项目类别:
Next generation drugs for bipolar depression and maintenance
用于双相抑郁症和维持治疗的下一代药物
- 批准号:
10080262 - 财政年份:2018
- 资助金额:
$ 11.92万 - 项目类别:
Next generation drugs for bipolar depression and maintenance
用于双相抑郁症和维持治疗的下一代药物
- 批准号:
10588254 - 财政年份:2018
- 资助金额:
$ 11.92万 - 项目类别: